Literature DB >> 16279296

The role of measurement reliability in clinical trials.

John M Lachin1.   

Abstract

One of the principal characteristics of an outcome measure in a clinical trial, and any measurement in general, is its reliability. Reliability refers to the reproducibility of the measurement when repeated at random in the same subject or specimen. Reliability is often confused with validity, which refers to the extent to which the variable properly measures the underlying trait of interest. The coefficient of reliability is an estimate of the proportion of all variation that is not due to measurement error and is readily estimated from replicate measurements. The reliability of a measurement determines its maximal correlation or R2 and slope (or effect size) in regression models, its sensitivity and specificity when used for classifications or predictions, and the power of a statistical test employing the measurement. All decline as the reliability of the measure declines. The reliability of a measurement is an important consideration in the choice of the primary outcome measure for a clinical trial and in the choice of measures used for assessment of eligibility and exclusion. Reliability of measures should be assessed and assured by a quality control program based on randomly selected duplicate assessments. Just as the power of a study is reported in a final publication, so also should the reliability of the outcome and eligibility measurements so as to allow the authors to better describe, and readers to better understand, the sources of imprecision in study results, and those who follow to improve the design of future trials.

Entities:  

Mesh:

Year:  2004        PMID: 16279296     DOI: 10.1191/1740774504cn057oa

Source DB:  PubMed          Journal:  Clin Trials        ISSN: 1740-7745            Impact factor:   2.486


  77 in total

1.  Assessment of early diastolic strain-velocity temporal relationships using spatial modulation of magnetization with polarity alternating velocity encoding (SPAMM-PAV).

Authors:  Ziheng Zhang; Donald P Dione; Peter B Brown; Erik M Shapiro; Albert J Sinusas; Smita Sampath
Journal:  Magn Reson Med       Date:  2011-05-31       Impact factor: 4.668

2.  Insulin secretion and impaired glucose tolerance.

Authors:  A B Jenkins; L V Campbell
Journal:  Diabetologia       Date:  2010-05-22       Impact factor: 10.122

3.  Computer-assisted navigation decreases the change in the tibial posterior slope angle after closed-wedge high tibial osteotomy.

Authors:  Dae Kyung Bae; Young Wan Ko; Sang Jun Kim; Jong Hun Baek; Sang Jun Song
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2016-02-11       Impact factor: 4.342

4.  Analytical and biological variation of biomarkers of oxidative stress during the menstrual cycle.

Authors:  Richard W Browne; Michael S Bloom; Enrique F Schisterman; Kathy Hovey; Maurizio Trevisan; Chengqing Wu; Aiyi Liu; Jean Wactawski-Wende
Journal:  Biomarkers       Date:  2008-03       Impact factor: 2.658

Review 5.  Alzheimer's disease drug development in 2008 and beyond: problems and opportunities.

Authors:  Robert E Becker; Nigel H Greig
Journal:  Curr Alzheimer Res       Date:  2008-08       Impact factor: 3.498

6.  Variability in the components of high-density lipoprotein particles measured in human ovarian follicular fluid: a cross-sectional analysis.

Authors:  Michael S Bloom; Keewan Kim; Victor Y Fujimoto; Richard W Browne
Journal:  Fertil Steril       Date:  2014-02-26       Impact factor: 7.329

Review 7.  Why do so many drugs for Alzheimer's disease fail in development? Time for new methods and new practices?

Authors:  Robert E Becker; Nigel H Greig; Ezio Giacobini
Journal:  J Alzheimers Dis       Date:  2008-10       Impact factor: 4.472

8.  Neuropsychiatric clinical trials: should they accommodate real-world practices or set standards for clinical practices?

Authors:  Robert E Becker; Nigel H Greig
Journal:  J Clin Psychopharmacol       Date:  2009-02       Impact factor: 3.153

9.  An international collaboration to harmonize the quantitative plasma Epstein-Barr virus DNA assay for future biomarker-guided trials in nasopharyngeal carcinoma.

Authors:  Quynh-Thu Le; Qiang Zhang; Hongbin Cao; Ann-Joy Cheng; Benjamin A Pinsky; Ruey-Long Hong; Joseph T Chang; Chun-Wei Wang; Kuo-Chien Tsao; Ym Dennis Lo; Nancy Lee; K Kian Ang; Anthony T C Chan; K C Allen Chan
Journal:  Clin Cancer Res       Date:  2013-03-04       Impact factor: 12.531

10.  The Functional Living Index-Cancer: estimating its reliability based on clinical trial data.

Authors:  Annouschka Laenen; Ariel Alonso
Journal:  Qual Life Res       Date:  2010-02       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.